Sonia Jangra
A5060375881- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Respiratory viral infections research
- Immune Response and Inflammation
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- interferon and immune responses
- Virus-based gene therapy research
- Animal Virus Infections Studies
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- Infection Control and Ventilation
- Long-Term Effects of COVID-19
- Asthma and respiratory diseases
- Viral-associated cancers and disorders
- Neonatal Respiratory Health Research
- Dental Research and COVID-19
- Cardiovascular Disease and Adiposity
- COVID-19 and healthcare impacts
- Respiratory Support and Mechanisms
- Pancreatic function and diabetes
- Monoclonal and Polyclonal Antibodies Research
- Diabetes and associated disorders
- Vitamin C and Antioxidants Research
Icahn School of Medicine at Mount Sinai
2020-2025
Rockefeller University
2025
University of Hong Kong
2019-2023
Ghent University Hospital
2022
University of Maryland, Baltimore
2022
Mount Sinai Health System
2021
Tata Memorial Hospital
2010
Bhabha Atomic Research Centre
2010
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins interact with the eukaryotic translation machinery, and inhibitors of have potent antiviral effects. We found that drug plitidepsin (aplidin), which has limited clinical approval, possesses activity (90% inhibitory concentration = 0.88 nM) is more than remdesivir against SARS-CoV-2 in vitro by a factor 27.5, toxicity cell culture. Through use drug-resistant mutant, we show mediated through inhibition known target...
Repurposing drugs as treatments for COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has drawn much attention. Beginning with sigma receptor ligands and expanding to other from screening in field, we became concerned that phospholipidosis was a shared mechanism underlying antiviral activity of many repurposed drugs. For all 23 cationic amphiphilic tested, including hydroxychloroquine, azithromycin, amiodarone, four others already clinical trials,...
One year in the coronavirus disease 2019 (COVID-19) pandemic, first vaccines are being rolled out under emergency use authorizations. It is of great concern that newly emerging variants severe acute respiratory syndrome 2 (SARS-CoV-2) can escape antibody-mediated protection induced by previous infection or vaccination through mutations spike protein. The glutamate (E) to Lysine (K) substitution at position 484 (E484K) receptor binding domain (RBD) protein present rapidly spreading belonging...
Abstract The current COVID-19 (coronavirus disease 19) pandemic, caused by SARS-CoV-2, disproportionally affects the elderly and people with comorbidities like obesity associated type 2 diabetes mellitus. Small animal models are crucial for successful development validation of antiviral vaccines, therapies to study role that have on outcome viral infections. initially available SARS-CoV-2 isolates require adaptation in order use mouse angiotensin converting enzyme (mACE-2) entry receptor...
Abstract Patients with coronavirus disease 2019 (COVID-19) present increased risk for ischemic cardiovascular complications up to 1 year after infection. Although the systemic inflammatory response severe acute respiratory syndrome 2 (SARS-CoV-2) infection likely contributes this risk, whether SARS-CoV-2 directly infects coronary vasculature and attendant atherosclerotic plaques remains unknown. Here we report that viral RNA is detectable replicates in lesions taken at autopsy from COVID-19...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) encodes several proteins that inhibit host interferon responses. Among these, ORF6 antagonizes signaling by disrupting nucleocytoplasmic trafficking through interactions with the nuclear pore complex components Nup98-Rae1. However, roles and contributions of during physiological infection remain unexplored. We assessed role using recombinant viruses carrying a deletion or loss-of-function (LoF) mutation in ORF6. plays key...
Rapid development of COVID-19 vaccines has helped mitigating SARS-CoV-2 spread, but more equitable allocation is necessary to limit the global impact pandemic and emergence additional variants concern. We have developed a vaccine candidate based on Newcastle disease virus (NDV) that can be manufactured at high yields in embryonated eggs. Here, we show NDV vector expressing an optimized spike antigen (NDV-HXP-S) versatile inducing protective antibody responses. NDV-HXP-S administered...
Abstract The search for vaccines that protect from severe morbidity and mortality because of infection with acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus causes disease 2019 (COVID‐19) is a race against clock virus. Here we describe an amphiphilic imidazoquinoline (IMDQ‐PEG‐CHOL) TLR7/8 adjuvant, consisting conjugated to chain end cholesterol‐poly(ethylene glycol) macromolecular amphiphile. It water‐soluble exhibits massive translocation lymph nodes upon local...
Concerns that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of disease 2019 (COVID-19), may cause new-onset diabetes persist in an evolving research landscape, and precise risk assessment is hampered by, at times, conflicting evidence. Here, leveraging comprehensive single-cell analyses vitro SARS-CoV-2-infected human pancreatic islets, we demonstrate productive strictly dependent on SARS-CoV-2 entry receptor ACE2 targets practically all...
Epstein-Barr virus (EBV) has developed effective strategies to evade host innate immune responses. Here we reported on mitigation of type I interferon (IFN) production by EBV deubiquitinase (DUB) BPLF1 through cGAS-STING and RIG-I-MAVS pathways. The two naturally occurring forms exerted potent suppressive effect cGAS-STING-, RIG-I- TBK1-induced IFN production. observed suppression was reversed when DUB domain rendered catalytically inactive. activity also facilitated infection counteracting...
Abstract Effective treatments against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) are urgently needed. Monoclonal antibodies have shown promising results in patients. Here, we evaluate the vivo prophylactic and therapeutic effect of COVA1-18, a neutralizing antibody highly potent B.1.1.7 isolate. In both settings, SARS-CoV-2 remains undetectable lungs treated hACE2 mice. Therapeutic treatment also causes reduction viral loads Syrian hamsters. When administered at 10 mg kg-1...
Some lytic proteins encoded by Epstein-Barr virus (EBV) suppress host interferon (IFN) signaling to facilitate viral replication. In this study, we sought identify and characterize EBV antagonizing IFN signaling. The induction of IFN-stimulated genes (ISGs) IFN-β was effectively suppressed EBV. A functional screen therefore performed IFN-antagonizing tegument protein BGLF2 identified as a potent suppressor JAK-STAT This activity found be independent its stimulatory effect on p38 JNK...
SARS-CoV-2, the etiologic agent of COVID-19, uses ACE2 as a cell entry receptor. Soluble has been shown to have neutralizing antiviral activity but short half-life and no active transport mechanism from circulation into alveolar spaces lung. To overcome this, we constructed an ACE2-human IgG1 fusion protein with mutations in catalytic domain ACE2. A mutation ACE2, MDR504, significantly increased binding SARS-CoV-2 spike protein, well variant, vitro more potent viral neutralization plaque...
Abstract Due to differences in human and murine angiotensin converting enzyme 2 (ACE-2) receptor, initially available SARS-CoV-2 isolates could not infect mice. Here we show that serial passaging of USA-WA1/2020 strain mouse lungs results “mouse-adapted” (MA-SARS-CoV-2) with mutations S, M, N genes, a twelve-nucleotide insertion the S gene. MA-SARS-CoV-2 infection causes mild disease, more pronounced morbidity depending on genetic background aged obese Two gene associated adaptation (N501Y,...
Coronavirus disease 2019 (COVID-19) in humans has a wide range of presentations, ranging from asymptomatic or mild symptoms to severe illness. Suitable animal models mimicking varying degrees clinical manifestations could expedite development therapeutics and vaccines for COVID-19. Here we demonstrate that acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulted subclinical rhesus macaques with pneumonia Syrian hamsters pneumonia. SARS-CoV-2 was confirmed by formalin-fixed,...
Abstract The germicidal potential of specific wavelengths within the electromagnetic spectrum is an area growing interest. While ultra-violet (UV) based technologies have shown satisfactory virucidal potential, photo-toxicity in humans coupled with UV associated polymer degradation limit their use occupied spaces. Alternatively, longer less irradiation energy such as visible light (405 nm) largely been explored context bactericidal and fungicidal applications. Such studies indicated that 405...
Several SARS-CoV-2 vaccines have received EUAs, but many issues remain unresolved, including duration of conferred immunity and breadth cross-protection. Adjuvants that enhance shape adaptive immune responses confer broad protection against variants will be pivotal for long-term as drift continue to emerge. We developed an intranasal, rationally designed adjuvant integrating a nanoemulsion (NE) activates TLRs NLRP3 with RNA agonist RIG-I (IVT DI). The combination spike protein antigen...
Abstract Poly(I:C) is a synthetic analogue of dsRNA capable activating both TLR3 and RLRs, such as MDA‐5 RIG‐I, pathogen recognition receptors. While poly(I:C) known to provoke robust type I IFN, III Th1 cytokine response, its therapeutic use vaccine adjuvant limited due vulnerability nucleases poor uptake by immune cells. encapsulated into lipid nanoparticles (LNPs) containing an ionizable cationic that can electrostatically interact with poly(I:C). LNP‐formulated triggered lysosomal...
We and others have previously shown that the SARS-CoV-2 accessory protein ORF6 is a powerful antagonist of interferon (IFN) signaling pathway by directly interacting with Nup98-Rae1 at nuclear pore complex (NPC) disrupting bidirectional nucleo-cytoplasmic trafficking. In this study, we further assessed role during infection using recombinant viruses carrying either deletion or well characterized M58R loss-of-function mutation in ORF6. show plays key antagonism IFN viral pathogenesis...
Abstract A well-tolerated and cost-effective oral drug that blocks SARS-CoV-2 growth dissemination would be a major advance in the global effort to reduce COVID-19 morbidity mortality. Here, we show FDA-approved nitazoxanide (NTZ) significantly inhibits viral replication infection different primate human cell models including stem cell-derived alveolar epithelial type 2 cells. Furthermore, NTZ synergizes with remdesivir, it broadly of variants B.1.351 (beta), P.1 (gamma), B.1617.2 (delta)...
Abstract Particulate respirators such as N95s are an essential component of personal protective equipment (PPE) for front-line workers. This study describes a rapid and effective UVC irradiation system that would facilitate the safe re-use N95 provides supporting information deploying decontamination SARS-CoV-2 during COVID-19 pandemic. To assess inactivation potential proposed germicidal device function time by using 3 M 8211-N95 particulate inoculated with SARS-CoV-2. A to deliver tailored...